Concurrent use of methylphenidate, bupropion, and erythromycin may lead to severe drug interactions resulting in myocardial infarction.
Warrants vigilance for rare interactions in polypharmacy; single case leaves open causality and broader risk assessment.
The prevalence and treatment of behavioral and mental illnesses in the adolescent population are increasing, and many of the medications used are continued into adulthood. Increased vigilance is necessary when caring for this population to prevent side effects and drug interactions. In this short communication, we present a case of myocardial infarction in a male likely related to drug interactions between bupropion, erythromycin, and methylphenidate.
No takes yet. Share an insight, caveat, or question.
George et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: